CD68 and persistent truncus arteriosus: In our study, the numbers of myocardial LYVE-1-labeled lymphatic vessels and CD68 macrophages began to increase one week after TAC and continued to increase through four weeks after TAC; however, both were reduced by LCZ696 treatment.